Wednesday, 29 February 2012

OncoSec Medical featured in Medical Device & Diagnostic Industry mag

OncoSec Medical (OTC:ONCS) has been featured in the magazine Medical Device & Diagnostic Industry, the company said Wednesday.
The biomedical company, founded in 2011, develops advance-stage ElectroOncology anti-cancer therapies to treat people with solid tumours.
The March article titled “OncoSec Could Revolutionize Oncology Therapy” details the company’s promising OMS ElectroOncology treatment platform. The article can be accessed here:
The magazine noted OncoSec’s on-going Phase II clinical studies in metastatic melanoma and Merkel cell carcinoma, a rare and aggressive cancer.
The article also notes the company’s upcoming milestones for this year.
The magazine is published monthly and written expressly for original equipment manufacturers of medical devices and in vitro diagnostic products.
It has a circulation of about 50,500, and its goal is to aide industry professionals in the design, and development of medical products that comply with regulations and market requirements.
On Tuesday, OncoSec announced that it dosed its first patient in a Phase II clinical trial testing its OMS ElectroImmunotherapy treatment on advanced-stage metastatic melanoma patients.
The dosing comes as the University of California San Francisco (UCSF) received approval from the Investigational Review Board for the trial. UCSF investigators are currently recruiting for this clinical trial.
OncoSec uses its electroporation delivery system which applies cell membrane stimulation to deliver immunotherapy or chemotherapy to treat a range of cancerous tumour types.
The OMS electroporation system has proven to enhance cellular uptake, effectively treating cancerous cells while sparing surrounding healthy tissue – cutting through the toxic side effects of current available treatment options like chemotherapy and radiation.
In 2011, the company managed to outline a clinical development plan for its local and potentially systemic ElectroImmunotherapy program, which uses the OncoSec Medical System (OMS) to deliver a DNA-based immunotherapy, known as DNA IL-12, designed to induce a local immune response against the treated cancerous tumor, while exploiting this response to initiate a global systemic response against untreated tumors in other areas of the body.
For the metastatic melanoma trial, a total of up to 25 patients with stage three or four cutaneous and in-transit metastatic melanoma will be enrolled in the phase two, single-arm, open-label and multi-centre study.

No comments:

Post a Comment